Price
CHART BY
Frequently asked questions
What is Gossamer Bio's market capitalization?
The market capitalization of Gossamer Bio is $67.16M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Gossamer Bio?
Gossamer Bio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$55.67. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Gossamer Bio's stock?
Currently, 7 analysts cover Gossamer Bio's stock, with a consensus target price of $122.48. Analyst ratings provide insights into the stock's expected performance.
What is Gossamer Bio's revenue over the trailing twelve months?
Over the trailing twelve months, Gossamer Bio reported a revenue of $53.29M.
What is the EBITDA for Gossamer Bio?
Gossamer Bio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$157.69M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Gossamer Bio?
Gossamer Bio has a free cash flow of -$164.59M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Gossamer Bio have, and what sector and industry does it belong to?
Gossamer Bio employs approximately 162 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Gossamer Bio's shares?
The free float of Gossamer Bio is 5.60M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $67.16M
- EPS (TTM)
- -$55.67
- Free Float
- 5.60M
- Revenue (TTM)
- $53.29M
- EBITDA (TTM)
- -$157.69M
- Free Cashflow (TTM)
- -$164.59M
Pricing
- 1D span
- $9.867$10.94
- 52W span
- $9.184$309.20
Analyst Ratings
The price target is $122.48 and the stock is covered by 7 analysts.
Buy
3
Hold
3
Sell
1
Information
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.
- Employees
- 162
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- GOSS
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet